Key Takeaways
- Novartis AG has agreed to acquire Avidity Biosciences in a significant $12 billion deal, paying $72 per share, representing a 46% premium, to bolster its late-stage neuroscience pipeline and expand its presence in RNA therapeutics.
- Palantir Technologies (PLTR) is set to sign a letter of intent with the Polish Defence Ministry on Monday, signaling deepening cooperation in the defense sector.
- Major Hurricane Melissa is under investigation by an Air Force Hurricane Hunter, with life-threatening floods anticipated in Jamaica and Southern Hispaniola.
- The Rapid Support Forces (RSF) claim a significant military achievement in Al-Fashir, Sudan, by controlling the army's command, marking a critical turning point in the ongoing conflict.
Swiss pharmaceutical giant Novartis AG (NVS) has announced a definitive agreement to acquire Avidity Biosciences (RNA) for $12 billion. The acquisition price of $72 per share represents a substantial 46% premium over Avidity's recent trading levels. This strategic move aims to significantly strengthen Novartis's late-stage neuroscience pipeline and expand its capabilities in the rapidly evolving field of RNA therapeutics. Ahead of the closing, Avidity Biosciences is expected to spin off its early-stage precision cardiology assets.
The acquisition aligns with Novartis's aggressive deal-making strategy to bolster its drug pipeline and offset looming patent cliffs for some of its best-selling drugs. Avidity Biosciences, a biotech firm focused on rare diseases, has three drugs in clinical trials targeting various forms of muscular dystrophy. Its promising assets include delpacibart zotadirsen (del-zota), an investigational antibody-oligonucleotide conjugate (AOC) for Duchenne muscular dystrophy, which has shown encouraging results in early trials and received Breakthrough Therapy designation from the FDA. Analysts have noted Avidity's leadership in muscular RNAi therapies, identifying potential multi-billion dollar opportunities in neuromuscular indications that currently lack disease-modifying treatments. The news of a potential takeover had previously caused Avidity's shares to surge significantly.
In other corporate news, Palantir Technologies Inc. (PLTR) is scheduled to sign a letter of intent on Monday with the Polish Defence Ministry. While specific details of the agreement were not immediately disclosed, cooperation between Palantir and the Polish Defence Ministry reportedly began in December of last year. This development suggests a deepening partnership between the data analytics software company and Poland's defense sector.
Meanwhile, a significant weather event is unfolding in the Caribbean. Air Force Hurricane Hunters are currently investigating Major Hurricane Melissa, which poses a severe threat to Jamaica and Southern Hispaniola. The hurricane is expected to bring life-threatening flash floods and landslides to these regions. As of Sunday, Hurricane Melissa was sustaining winds of 140 mph, classifying it as a Category 4 hurricane, and was expected to strengthen further.
On the geopolitical front, an advisor to the leader of the "Rapid Support Forces" (RSF) in Sudan has claimed a major military achievement in Al-Fashir. The advisor stated that the RSF has gained control of the army's command in the city, describing it as a "very important turning point" and facilitating advances on other areas. The advisor also indicated that over 40,000 soldiers were present in Al-Fashir. This development comes amidst a tightening siege by the paramilitary RSF on El-Fasher, which has been the epicenter of intense fighting and a dire humanitarian crisis for over a year. The UN has repeatedly raised alarms about the rapidly deteriorating situation and the devastating impact on civilians in the besieged city.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.